Medical devices, healthcare technology and the business of care
COMPANY INTELLIGENCE

Cardiva Medical, Inc.

Explore this company’s associated devices, FDA decisions and regulatory history.

Clinical monitoring equipment, editorial photography

Cardiva Medical, Inc.

Regulatory records
4
Linked recall entries
0
Headquarters
Not reported
Brand website
Not reported
COMPANY INTELLIGENCE

What the linked records show

MedtechLedger currently links 4 FDA records to the applicant name Cardiva Medical, Inc.. It includes 1 original PMA approval. 2 entries are PMA supplements. 1 entry is a 30-day notice. These are records held by this publication, rather than a count of the company’s entire portfolio.

The dated entries run from Jan 31, 2013 to Sep 10, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.

Product code MGB appears in 4 of the 4 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.

The largest PMA family in this collection is P120016, with 4 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 2 linked filings have a current plain-language explanation checked against the recorded FDA decision.

Applicant mailing address recorded by FDA: 2900 Lakeside Dr., Suite 160, Santa Clara, CA, 95054. Recorded on P120016/S043, decision dated Sep 10, 2026.

Changes described in PMA records

P120016/S043: VASCADE 5F Vascular Closure System

The FDA recorded decision OK30 on 2026-09-10 for P120016/S043, a 30-Day Notice supplement to the VASCADE 5F Vascular Closure System (Model 700-500DX) held by Cardiva Medical, Inc. The supplement reason is listed as a process change covering manufacturer, sterilizer, packager or supplier. The recorded statement describes an additional supplier for the collagen plug component of the device.

This action concerns the supply arrangement for one component rather than a new approval of the whole system. The device is categorized as a vascular hemostasis device in the cardiovascular specialty under product code MGB. The source record does not identify the added supplier, the site involved, or any supporting documents, and it gives no clinical or performance data; those details remain unknown from this record.

Whether the supplier change affects collagen plug performance or requires further review is not addressed in the available fields, so no clinical or legal conclusion is drawn here.

FDA approval-order wording

an additional supplier for the collagen plug component of the VASCADE 5F (Model 700-500DX)

Sep 10, 2026 · 30-Day Notice

P120016/S040: Cardiva, VASCADE Family

FDA’s recorded scope: an additional supplier for the collagen plug component of the VASCADE 6/7F (Model 700-580I) and VASCADE MVP Venous Vascular Closure System (VVCS) (Model 800-612C) devices

Apr 23, 2026 · 135 Review Track For 30-Day Notice

P120016/S039: VASCADE MVP XL VVCS Model 800-1014XL

FDA’s recorded scope: The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is indicated for the percutaneous closure of femoral venous access sites while reducing time to ambulation, total post-procedure time, time to hemostasis, and time to discharge eligibility in patients who have undergone catheter-based procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs. The VASCADE MVP XL Venous Vascular Closure System (VVCS) Model 800-1014XL is also indicated for enabling same day discharge in patients who have undergone catheter-based cardiac arrhythmia ablation procedures utilizing 8 14F inner diameter (17F maximum outer diameter) procedural sheaths, with single or multiple access sites in one or both limbs.

Mar 27, 2026 · Panel Track

P120016: VASCADE VASCULAR CLOSURE SYSTEM

FDA approved the VASCADE Vascular Closure System under PMA P120016 on January 31, 2013. The approval covers femoral arterial access site closure while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures using a 5F, 6F, or 7F procedural sheath.

The approval also covers reducing time to discharge eligibility, but only for patients who have undergone diagnostic endovascular procedures using a 5F, 6F, or 7F procedural sheath. The statement does not include safety or effectiveness data, and the source fields do not identify any supplement or change to a prior PMA.

FDA approval-order wording

APPROVAL FOR THE VASCADE¿ VASCULAR CLOSURE SYSTEM (VCS). THIS DEVICE IS INDICATED FOR FEMORAL ARTERIAL ACCESS SITE CLOSURE WHILE REDUCING TIMES TO HEMOSTASIS AND AMBULATION IN PATIENTS WHO HAVEUNDERGONE DIAGNOSTIC OR INTERVENTIONAL ENDOVASCULAR PROCEDURES USING A 5F, 6F, OR 7F PROCEDURAL SHEATH. THE VASCADE VCS IS ALSO INDICATED TO REDUCE TIME TO DISCHARGE ELIGIBILITY IN PATIENTS WHO HAVE UNDERGONE DIAGNOSTIC ENDOVASCULAR PROCEDURES USING A 5F, 6F, OR 7F PROCEDURAL SHEATH.

Jan 31, 2013

Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.

Regulatory record history

Product / regulatory recordCompanyPathwayDecision dateSource
Cardiva Medical, Inc.PMA supplementSep 10, 2026FDA
Cardiva Medical, Inc.PMA supplementApr 23, 2026FDA
Cardiva Medical, Inc.PMA supplementMar 27, 2026FDA
Cardiva Medical, Inc.PMA approvalJan 31, 2013FDA
Source information

Source updated Nov 9, 2026. Retrieved Nov 21, 2026.